Vanguard Group Inc. Purchases 741,451 Shares of Evolus, Inc. (NASDAQ:EOLS)

Vanguard Group Inc. grew its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 37.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,698,647 shares of the company's stock after purchasing an additional 741,451 shares during the quarter. Vanguard Group Inc. owned about 4.72% of Evolus worth $24,666,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Legal & General Group Plc lifted its stake in shares of Evolus by 8.4% in the 4th quarter. Legal & General Group Plc now owns 14,458 shares of the company's stock valued at $109,000 after purchasing an additional 1,116 shares during the period. Rhumbline Advisers raised its stake in Evolus by 2.2% during the 1st quarter. Rhumbline Advisers now owns 55,620 shares of the company's stock worth $471,000 after buying an additional 1,180 shares during the period. Sei Investments Co. raised its stake in Evolus by 4.7% during the 1st quarter. Sei Investments Co. now owns 26,991 shares of the company's stock worth $228,000 after buying an additional 1,222 shares during the period. Bank of New York Mellon Corp raised its stake in Evolus by 1.1% during the 1st quarter. Bank of New York Mellon Corp now owns 123,548 shares of the company's stock worth $1,045,000 after buying an additional 1,285 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in Evolus by 13.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 12,345 shares of the company's stock worth $113,000 after buying an additional 1,484 shares during the period. 90.69% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Rui Avelar sold 27,603 shares of the company's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total value of $384,233.76. Following the completion of the transaction, the insider now directly owns 372,288 shares of the company's stock, valued at $5,182,248.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Evolus news, insider Rui Avelar sold 27,603 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $384,233.76. Following the completion of the transaction, the insider now directly owns 372,288 shares of the company's stock, valued at $5,182,248.96. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Moatazedi sold 7,706 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $13.08, for a total value of $100,794.48. Following the transaction, the insider now directly owns 792,416 shares of the company's stock, valued at $10,364,801.28. The disclosure for this sale can be found here. Insiders sold a total of 60,969 shares of company stock valued at $831,005 over the last three months. Corporate insiders own 5.40% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on EOLS shares. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Evolus in a research note on Friday, March 1st. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday. Finally, Barclays raised Evolus from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $10.00 to $16.00 in a research note on Monday, January 29th.

Evolus Stock Performance

Shares of Evolus stock traded down $0.60 on Friday, hitting $12.09. The company had a trading volume of 321,699 shares, compared to its average volume of 539,215. The stock has a market capitalization of $700.49 million, a price-to-earnings ratio of -11.09 and a beta of 1.45. Evolus, Inc. has a 1 year low of $7.07 and a 1 year high of $15.43. The stock has a 50 day moving average of $13.74 and a 200-day moving average of $11.07.

Evolus (NASDAQ:EOLS - Get Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $61.00 million during the quarter, compared to the consensus estimate of $61.14 million. Equities analysts anticipate that Evolus, Inc. will post -0.51 earnings per share for the current year.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.